Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Rpmdt

Research Leaders

5 sponsors active, led by Nordic Lymphoma Group

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 2 (2)

Trial Status

Recruiting3
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07137494Phase 1RecruitingPrimary

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

NCT07604987Phase 2RecruitingPrimary

R-PMDT Regimen in Newly Diagnosed PCNSL

NCT06439420Phase 2Completed

CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial

NCT06755619RecruitingPrimary

CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)

Showing all 4 trials

Research Network

Common Treatments

  • Rpmdt1
  • Cognitive Behavioral Therapy For Insomnia1
  • Mbcart191 Cellular Therapy1

Active Sponsors

  • Nordic Lymphoma Group1
  • Zou Dehui1
  • Memorial Sloan Kettering Cancer Center1
  • Miltenyi Biomedicine GmbH1
  • Virginia Commonwealth University1

Top Investigators

Related Conditions

  • Meningioma1
  • Oligodendroglioma1
  • Primary Brain Tumor1
  • Secondary Central Nervous System Lymphoma1
  • Glioblastoma1

Activity Timeline